Long term safety and efficacy of ligelizumab in the treatment of Japanese patients with chronic spontaneous urticaria

Long term safety and efficacy of ligelizumab in the treatment of Japanese patients with chronic spontaneous urticaria

Background: In Japan, urticaria is a common skin disorder with chronic spontaneous urticaria (CSU) being the most frequent subtype. This study evaluated the safety of ligelizumab (anti-IgE monoclonal antibody) in Japanese CSU patients. Methods: This was a Phase 3 multicenter, open-label, single-arm...

Full description

Saved in:
Bibliographic Details
Main Authors: Hidetoshi Takahashi, Atsushi Fukunaga, Koremasa Hayama, Takayoshi Sasajima, Ayako Fujishige, Ryohei Ichishita, Naoko Tomimatsu, Eva Hua, Vineeth Varanasi, Alis Burciu, Michihiro Hide, Thomas Severin
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Allergology International
Subjects:
Chronic spontaneous urticaria
IgE
Japanese
Ligelizumab
Long-term adverse events
Online Access:http://www.sciencedirect.com/science/article/pii/S1323893024001072
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items